Table 3 Eligible number of patients, total costs, and budget impact of adding TXA to standard care treatment for PPH management
| Â | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Total number of PPH patients in India | 643,226 | 676,439 | 666,150 | 596,409 | 471,710 |
Current Scenario—patients eligible for available standard care | 643,226 (100%) | 676,439 (100%) | 666,150 (100%) | 596,409 (100%) | 471,710 (100%) |
Bottom-up uptake of TXA intervention | 119,704 (19%) | 348,637 (52%) | 666,150 (100%) | 596,409 (100%) | 471,710 (100%) |
Standard treatment care uptake with TXA introduction | 523,521 (81%) | 327,803 (48%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Â | The total cost of PPH management with tranexamic acid addition | The total cost of PPH management without tranexamic acid addition | Budget impact (difference) | Percentage impact (% difference) | |
2021 | INR 4,212,816,600 USD 60,670,189 | INR 4,187,661,060 USD 60,307,916 | INR 25,155,540 USD 362,273 | 0.6% | |
2022 | INR 4,477,159,957 USD 64,477,087 | INR 4,403,894,864 USD 63,421,972 | INR 73,265,093 USD 1,055,115 | 1.7% | |
2023 | INR 4,476,894,328 USD 64,473,261 | INR 4,336,904,772 USD 62,457,225 | INR 139,989,556 USD 2,016,037 | 3.2% | |
2024 | INR 4,008,198,438 USD 57,723,414 | INR 3,882,864,695 USD 55,918,441 | INR 125,333,742 USD 1,804,973 | 3.2% | |
2025 | INR 3,170,151,163 USD 45,654,413 | INR 3,071,022,610 USD 44,226,830 | INR 99,128,552 USD 1,427,584 | 3.2% | |
Cumulative | INR 20,345,220,485 USD 292,998,365 | INR 19,882,348,001 USD 286,332,383 | INR 462,872,485 USD 6,665,982 | 2.3% | |